Effect of Rosuvastatin on Endothelial Function

Inclusion Criteria: * HIV infection * Age \> 18 years old * On stable antiretroviral therapy for \> 6 months with no plans to change therapy during the treatment phase of the study * Plasma HIV RNA \< 50 copies/mL * Karnofsky performance score \> 70 within 30 days prior to study entry * Ability to understand and sign informed consent * Following laboratory values obtained within 30 days prior to randomization: * Absolute neutrophil count (ANC) \> 750/mm3 * Hemoglobin \>/= 8.0 g/dL * Platelets \>/= 50,000/mm3 * ALT (SGPT) and AST (SGOT) \< 2.5 x ULN * Fasting glucose \< 126 mg/dL * TSH \< 3.0 mIU/L * HDL-C \< 50 mg/dL in men, \< 55 mg/dL in women * Direct LDL-C \</= 130 mg/dL * Calculated creatinine clearance \> 50 mL/min * Willing to be treated with rosuvastatin or be on an observational arm for a minimum of 3 months * Female subject must not participate in a conception process (active attempt to become pregnant) or be post-menopausal. If participating in sexual activity that could lead to pregnancy, the subject must use contraception while receiving study medication and 30 days after stopping the medication Exclusion criteria * History of past cardiovascular event * Acute illnesses or active AIDS-defining opportunistic infection (OI) within 30 days prior to entry * Other chronic illness including diabetes, autoimmune diseases, and endocrinopathies * Serology positive for hepatitis B surface antigen or hepatitis C antibody * Signs and symptoms of liver failure * Receipt of supraphysiologic glucocorticoid therapy within 3 months prior to study entry * Use of lipid lowering agents within 30 days prior to study entry * Receipt of an HIV vaccine or investigational agents * Pregnancy or breast-feeding * Presence of any active malignancy within the last 5 years * Severe Hypertension (Systolic \>/= 180 or Diastolic \>/= 110 mm Hg) * Use of oral postmenopausal hormone replacement therapy * Known hypersensitivity to rosuvastatin * Active drug or alcohol dependence * Any acute illness within 30 days prior to study entry that, in the opinion of the site investigator, would interfere with participation in the study. * Use of lopinavir/ritonavir (Kaletra) as part of current HIV antiretroviral regimen